PDCD1 and renal cell carcinoma: ICIs targeting CTLA-4, PD-1 and PD-L1 have dramatically improved survival rates across diverse cancer types, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), hepatocellular carcinoma, and triple negative breast cancer.